​

Orchestra BioMed Stock (NASDAQ:OBIO)

ForecastRevenueOwnershipFinancialsChart
Orchestra BioMed by TradingView

Previous Close

$4.60

52W Range

$2.20 - $5.42

50D Avg

$4.19

200D Avg

$3.54

Market Cap

$247.32M

Avg Vol (3M)

$205.41K

Beta

0.59

Div Yield

-

OBIO Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

70

IPO Date

Aug 04, 2020

Website

OBIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product$611.00K$633.00K$654.00K

Fiscal year ends in Dec 25 | Currency in USD

OBIO Financial Summary

Dec 25Dec 24Dec 23
Revenue$33.48M$2.64M$2.76M
Operating Income$-51.81M$-64.30M$-51.51M
Net Income$-52.95M$-61.02M$-49.12M
EBITDA$-51.81M$-63.99M$-51.22M
Basic EPS$-1.11$-1.66$-1.48
Diluted EPS$-1.11$-1.66$-1.48

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PYXSPyxis Oncology, Inc.
ENTAEnanta Pharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
AVTXAvalo Therapeutics, Inc.
TARAProtara Therapeutics, Inc.
PRLDPrelude Therapeutics Incorporated
IVVDInvivyd, Inc.
IVAInventiva S.A.
EPRXEupraxia Pharmaceuticals Inc.
CRBUCaribou Biosciences, Inc.